“AEGEAN underscores our commitment to transforming care in the early stages of lung cancer where there is the greatest potential for cure.” In subjects treated with the Imfinzi-based perioperative regimen, the planned interim analysis findings of event-free survival demonstrated a 32% decrease in ...
Dave Fredrickson, Executive Vice President, Oncology Business Unit,AstraZeneca, said: “This approval for IMFINZI marks a breakthrough for patients with limited-stage small cell lung cancer, allowing them to receive immunotherapy for the first time. The ADRIATIC trial showed an improvement in median ...